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Objectives—The purpose of this study was to compare hepatic stiffness on ultra-
sound (US) shear wave elastography (SWE) in patients with chronic graft-versus-
host disease (GVHD) after allogeneic hematopoietic stem cell transplantation
versus patients with no underlying liver disease.
Methods—We performed a retrospective analysis of 4901 patients who under-
went abdominal US examinations with adjunctive liver SWE between August
2014 and December 2016. Each patient was scanned supine with gentle breath
holding on LOGIQ E9 (GE Healthcare, Waukesha, WI) or Epiq (Philips Health-
care, Andover, MA) US machines (3–6 MHz). Three to 10 measurements were
made intercostally in the right hepatic lobe, following manufacturers’ guidelines
before release of the 2015 Society of Radiologists in Ultrasound consensus or
the 2015 Society of Radiologists in Ultrasound consensus. The median and stan-
dard deviation of the shear wave velocity (SWV) were obtained. A 2-sample
t test with the Welch approximation was used for statistical analysis.
Results—Six patients had documented hepatic chronic GVHD or a high clinical sus-
picion of liver chronic GVHD. All had normal pretransplant liver function test
results and no pretransplant or posttransplant hepatic infection. The control group,
obtained from the same database, contained 10 patients with normal liver function
test results, no abdominal pain, and no history of liver disease or conditions that
may have caused liver stiffness changes. The SWVs in patients with chronic GVHD
were double those in the control group (1.96 ± 0.28 versus 0.98 ± 0.27 m/s;
P < .0001).
Conclusions—Patients with chronic GVHD had substantially higher hepatic
parenchymal SWVs than patients without liver disease, indicating increased tissue
stiffness. To our knowledge, this phenomenon has not been previously reported in
chronic GVHD and suggests potential utility of SWE for diagnosis and monitoring
of disease progression and the treatment response in this cohort of patients.
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A llogeneic hematopoietic stem cell transplanta-tion (HSCT) is an effective therapy forleukemia and aplastic anemia, leading to more
long-term survivors.1 Chronic graft-versus-host disease
(GVHD) has been shown to be a leading cause of
nonrelapse mortality among long-term survivors after
transplantation.2 Chronic GVHD has been increasing
for several reasons, including expansion of the donor
population, peripheral blood cell transplantation, and
donor lymphocyte infusion for the treatment of
recurrent disease.3 Chronic GVHD may progress
directly from acute GVHD, follow a quiescent period,
or arise de novo even without a history of acute GVHD.
Among long-term transplant survivors, approxi-
mately 40% to 73% have chronic GVHD.4,5 The path-
ophysiologic mechanism of GVHD is that donor
lymphocytes attack and damage the bile canaliculi of
the recipients, causing cholestatic liver dysfunction,
which may eventually progress to cirrhosis. Liver mani-
festation is heralded by abnormal laboratory findings,
such as elevated serum bilirubin, alkaline phosphatase
(AP), and transaminase (aspartate aminotransferase
[AST] and alanine aminotransferase [ALT]) levels in
the setting of cutaneous or gastrointestinal tract
GVHD. However, abnormal liver function test results
are nonspecific for the diagnosis of hepatic GVHD.
Early diagnosis and robust surveillance methods are
essential to direct and assess treatment for this poten-
tially reversible disease. Currently, valid biomarkers and
specific imaging diagnoses of hepatic GVHD are largely
absent, although some imaging features on ultrasound
(US) imaging, computed tomography, and magnetic res-
onance imaging may suggest disease involvement in the
liver5: for instance, enhancement of the biliary tract and
thickened gallbladder wall, dilatation of the common bile
duct, biliary sludge, and pericholecystic fluid.
Currently, liver biopsy is the reference standard
for diagnosis and is required to document the disease.
However, limitations to biopsy do exist.6 First, post-
biopsy hemorrhage is a feared complication because
of hemodynamic instability and coagulopathy, which
may be life threatening. Second, these immunocom-
promised patients have an increased propensity to
biopsy-related infections. Finally, false-negative biopsy
results may occur from sampling errors, given the pat-
chy distribution of bile duct lesions. Therefore, devel-
opment of an effective noninvasive technique for the
early diagnosis and active surveillance of hepatic
chronic GVHD is desirable as a complementary or
alternative approach to liver biopsy.
Although there is a plethora of research docu-
menting the utility of US elastography in evaluation
of liver stiffness, there is limited research document-
ing its utility for hepatic disease processes such as
chronic GVHD, among which transient elastography
(e.g., FibroScan; Echosens North America, Waltham,
MA) and acoustic radiation force impulse imaging7
are the main techniques being investigated. Thus, the
goal of this study was to compare hepatic tissue stiff-
ness using US shear wave elastography (SWE) in
patients with chronic GVHD after allogeneic HSCT
versus patients with no underlying liver disease.
Materials and Methods
Patients and Study Overview (Definition of Hepatic
Chronic GVHD)
This work was an Institutional Review Board–approved,
Health Insurance Portability and Accountability Act–
compliant retrospective study, in which informed con-
sent was waived given the retrospective nature of the
study. A search of our database via the Electronic Medi-
cal Record Search Engine8 was performed from August
2014 to December 2016, which yielded 4901 patients
who underwent abdominal US examinations with con-
comitant liver SWE measurements. From this database,
2 separate groups were identified: a chronic GVHD
group and a control group.
Inclusion criteria for the chronic GVHD group
included those patients with either biopsy-proven hepatic
chronic GVHD or those who presented with cholestatic
liver dysfunction manifested by elevated serum bilirubin,
AP, or transaminase levels, and abdominal pain in the set-
ting of biopsy-proven cutaneous or gastrointestinal tract
GVHD, or both. These criteria yielded 6 patients.
Based on SWE values in the chronic GVHD
group, a power calculation was performed and indi-
cated that a control group of 10 patients would provide
90% power for detecting a difference of 0.5 m/s at a
significance level of less than .05, assuming equal vari-
ances. As such, we identified a control group of
10 patients from the overall database. Inclusion criteria
for the control group included: normal liver function
test results, no history of abdominal pain, and no his-
tory of underlying liver disease or conditions that may
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have caused altered liver stiffness (ie, hepatitis infection
and cardiovascular dysfunction). Patients in the control
group had abdominal US examinations with concomi-
tant liver SWE for one of the following reasons:
follow-up of appendicitis, weight loss, metastasis/malig-
nancy screening for ocular melanoma or breast cancer/
Li-Fraumeni syndrome, or evaluation of cholelithiasis.
Pertinent clinical data and laboratory values
within 3 months of the date of SWE were recorded
per patient in a Microsoft Excel file (Microsoft Cor-
poration, Redmond, WA), which included body mass
index, spleen length, total bilirubin, AP, ALT, AST,
hemoglobin levels, and platelet and leukocyte counts.
For the chronic GVHD group, pretransplant and
posttransplant laboratory values were obtained within
3 months before HSCT and within 7 months after
HSCT, respectively. The mean time ± SD between
HSCT and SWE in the chronic GVHD group was
15.8 ± 10.1 months.
Ultrasound and SWE Assessments
Abdominal US examinations with adjunctive SWE
were performed on LOGIQ E9 (GE Healthcare,
Waukesha, WI) or Epiq (Philips Healthcare, Andover,
MA) US machines by registered diagnostic medical
sonographers with at least 1 year of experience with
SWE. The US examination was performed with the
patient fasting for a minimum of 4 hours before the
examination. The patient was placed in the supine
position with elevation of the right arm above the
head. Three- to 6-MHz curved linear transducers
were used to image the liver, and static and cine gray-
scale and color Doppler images were obtained.
Hepatic shear wave velocities (SWVs) were
obtained while the patient performed a short period
of gentle shallow breath holding, avoiding deep inspi-
ration or the Valsalva maneuver. Three to 10 SWV
measurements were made in the intercostal position
with the transducer placed over a homogeneous area
of parenchyma within the right hepatic lobe, follow-
ing manufacturers’ guidelines before release of the
2015 Society of Radiologists in Ultrasound consensus
or the 2015 Society of Radiologists in Ultrasound
consensus.9 Regions of interest measured at least
1 cm2 and were placed 1.5 to 2 cm below and per-
pendicular to the hepatic capsule and at least 1 cm
apart from the gallbladder and any adjacent large
vessels (Figures 1 and 2).
Figure 1. Shear wave elastography of the liver of a patient in the control group.
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Retrospective US imaging interpretation was
performed, in which images were reviewed on
Syngo Dynamics workstations (Siemens Healthi-
neers, Mountain View, CA) by an abdominal imag-
ing fellow with 6 years of research experience in US
elastography. Shear wave velocities of the patients
were recorded in a Microsoft Excel file.
Statistical Analysis
A 2-sample t test with the Welch approximation was
used for statistical analysis of SWVs. For patients’
demographic and laboratory findings, continuous vari-
ables were analyzed by t tests, and categorical vari-
ables were analyzed by the Fisher exact test. All
statistical tests were performed with Microsoft Excel,
assuming P < .05 for statistical significance.
Results
Six patients (5 female and 1 male; mean age, 51 years;
range, 21–69 years) were found to meet the inclusion
Figure 2. Shear wave elastography of the liver of a patient with hepatic chronic GVHD.
Table 1. History of HSCT and SWE of the 6 Patients With Hepatic Chronic GVHD
Patient Age, y Sex
Initial
Diagnosis
Transplantation
Date
Date of
Biopsy-Proven
Chronic GVHD
Date of
SWE
SWV,
m/s
1 69 Female AML 1/1/2015 9/18/2015 10/19/2015 2.1
2 60 Female AML 4/1/2015 12/3/2015 3/13/2016 1.9
3 54 Female AML 1/1/2014 OSH 2014 12/2/2016 2.3
4 43 Female AML 2/1/2015 3/11/2015 8/5/2016 2.1
5 60 Male AML 4/1/2014 11/14/2014 6/12/2015 1.8
6 21 Female ALL 3/1/2016 10/19/2016 11/22/2016 1.5
ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leukemia; and OSH, outside hospital.
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criteria of the chronic GVHD group. Of note, all had
biopsy-proven hepatic chronic GVHD. These
6 patients had normal pretransplantation liver func-
tion test results and no pretransplantation or post-
transplantation hepatic infection, with laboratory
values obtained within 3 months before and within
7 months after HSCT. The indications for liver US
were known chronic GVHD with elevated bilirubin,
AP, ALT, and AST levels, right upper abdominal
pain, or both. Table 1 summarizes the histories of
transplantation and SWE of these 6 patients. The
control group contained 10 patients (6 female and
4 male; mean age, 46 years; range, 25–69 years)
with normal liver function test results, no right
upper quadrant pain, and no history of liver disease
or conditions that may have caused liver stiffness
changes.
Patients’ demographic information and labora-
tory values are summarized in Table 2. The blood
count showed a lower hemoglobin level (P = .0007)
and platelet count (P = .036) in the chronic GVHD
group, which reached statistical significance. The
leukocyte count was also low in the chronic GVHD
group; however, statistical significance was not
reached. Although liver function test results were
abnormal in the chronic GVHD group, only the AP
level was significantly higher than that of the control
group (P = .0064). The SWVs in patients with chronic
Figure 3. Shear wave velocities in the control and disease groups. cGVHD indicates chronic GVHD.
Table 2. Patients’ Demographic Information and Laboratory Values
Parameter
Disease
Group
Control
Group P
Patients 6 10
Age, y 51 ± 17 46 ± 17 .23
Male/female 1/5 4/6 .33
Body mass index, kg/m2 29.0 ± 12.8 26.5 ± 3.0 .56
Spleen length, cm 11.8 ± 3.12 10.8 ± 1.7 .42
AP, U/L 427.8 ± 348.1 81.0 ± 35.2 .0064
Total bilirubin, mg/dL 1.3 ± 1.3 0.7 ± 0.1 .16
ALT, U/L 140.3 ± 181.6 21.4 ± 8.0 .053
AST, U/L 137.3 ± 199.7 22.8 ± 3.3 .084
Hemoglobin, g/dL 9.7 ± 2.4 13.8 ± 1.4 .0007
Platelets, × 103/μL 127.5 ± 116.6 247.5 ± 89.9 .036
Leukocytes, × 103/μL 5.0 ± 1.7 8.6 ± 4.4 .078
Data are presented as mean ± SD where applicable.
Zhang et al—Shear Wave Elastography of the Liver With Posttransplant Chronic GVHD
J Ultrasound Med 2019; 38:455–461 459
GVHD were double those in the control group
(median ± SD, 1.96 ± 0.28 versus 0.98 ± 0.27 m/s;
P < .0001; Figure 3).
Discussion
Chronic GVHD is one of the most common com-
plications of allo-HSCT and accounts for a sub-
stantial amount of nonrelapsing morbidity and
mortality. Despite a limited understanding of the
pathophysiologic mechanism of post-transplant
chronic GVHD, it appears to be related to inflam-
mation secondary to cell-mediated and humoral
immunity, eventually leading to fibrosis. Chronic
GVHD may progress directly from acute GVHD,
which carries a grim prognosis, may develop after a
quiescent period after prior acute GVHD flare-ups,
with an intermediate prognosis, or may arise de
novo without prior acute GVHD, which has a rela-
tively good prognosis.1,4
Diagnosing and grading of chronic GVHD have
been challenging because of an inadequate under-
standing of the pathophysiologic mechanism, lack of
biomarkers, and coexistent diseases. These factors can
also pose challenges to treatment in this patient pop-
ulation, given the difficulty in diagnosing not only the
disease but also the severity of the disease.
Hepatic chronic GVHD typically manifests as cho-
lestasis with laboratory abnormalities, showing elevated
AP, serum bilirubin, ALT, and AST levels with or with-
out right upper abdominal pain. The associated histo-
logic findings include lymphocytic infiltration of bile
ducts, damage to and loss of small bile ducts, portal
fibrosis, and necrosis. Ductopenic GVHD is potentially
reversible if immunologic destruction of ductal epithe-
lial cells is halted.10 Therefore, effective and timely
diagnosis is essential for successful treatment.
In this study, we have shown that patients with
chronic GVHD had statistically significantly higher
hepatic parenchymal SWVs than patients with no
underlying liver disease, indicating increased tissue
stiffness, which may relate to the effects of chronic
inflammation and portal fibrosis. To our knowledge,
this phenomenon has not been previously reported in
hepatic chronic GVHD and suggests the potential use
of US SWE for diagnosis and monitoring of disease
progression and the treatment response.
This preliminary retrospective study had some
limitations. First, the sample size was small. However,
we detected a statistical difference between the
groups, suggesting that our study was sufficiently
powered. Second, our study only included SWV mea-
surement at a single time point; thus, the reproduc-
ibility of the findings was not assessed. Further
studies with SWV measurements in patients with
GVHD or suspected GVHD should include SWVs
measured at different time points and should corre-
late them with the laboratory findings at those speci-
fied time points to assess the disease process or
treatment response. Third, we did not investigate
possible coexistent conditions such as hepatic veno-
occlusive disease, hepatic toxicity, and systemic com-
plications, including cardiopulmonary distress, which
may alter hepatic function.
In summary, our results indicate that patients with
liver chronic GVHD have greater liver stiffness and
resulting elevations in SWVs compared to healthy con-
trols. Given the importance of chronic GVHD as a
cause of treatment-related morbidity and mortality in
patients with leukemia or aplastic anemia after stem
cell transplantation, the need for noninvasive disease
monitoring is substantial. Although preliminary, our
results support the potential utility of US SWE for use
in guidance of diagnosis and treatment assessment in
this population of patients.
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